First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis

Background and objective Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐17A and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque psoriasis. Methods This study had two parts: single ascending d...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2021-05, Vol.35 (5), p.1143-1151
Hauptverfasser:	Kaul, M., Jarvis, P., Rozenberg, I., Kolbinger, F., Di Padova, F., Calonder, C., Espie, P., Rondeau, J.M., Cebe, R., Huber, T., Mussmann, R., Aassi, M., Sligh, T.S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - adverse effects Double-Blind Method Humans Interleukin-17 Original Psoriasis Psoriasis - drug therapy Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!